What is he best known for?
The fields of study he is best known for:
His main research concerns Genetics, Fragile X syndrome, Cell biology, Neurogenesis and Molecular biology.
In most of his Genetics studies, his work intersects topics such as Neurodegeneration.
His studies in Fragile X syndrome integrate themes in fields like Polysome, Messenger RNA, RNA-binding protein and FMR1.
His Messenger RNA research incorporates elements of Synaptic plasticity and microRNA.
His biological study deals with issues like Regulation of gene expression, which deal with fields such as Neuropathology.
His biological study spans a wide range of topics, including RNA, RNA splicing, Amyloid precursor protein, HEK 293 cells and 5-Hydroxymethylcytosine.
His most cited work include:
- Microarray Identification of FMRP-Associated Brain mRNAs and Altered mRNA Translational Profiles in Fragile X Syndrome (970 citations)
- Microarray Identification of FMRP-Associated Brain mRNAs and Altered mRNA Translational Profiles in Fragile X Syndrome (970 citations)
- Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure (942 citations)
What are the main themes of his work throughout his whole career to date?
Peng Jin mainly investigates Genetics, Epigenetics, Cell biology, DNA methylation and Fragile X syndrome.
His work on Genetics deals in particular with microRNA, Gene, Gene expression, RNA and Trinucleotide repeat expansion.
His RNA study typically links adjacent topics like Messenger RNA.
His Epigenetics study combines topics from a wide range of disciplines, such as Enhancer, 5-Hydroxymethylcytosine, Embryonic stem cell and Computational biology.
His work deals with themes such as Molecular biology, Cellular differentiation and Induced pluripotent stem cell, which intersect with Cell biology.
His Fragile X syndrome study incorporates themes from Drosophila melanogaster, Drosophila Protein, Polysome and FMR1.
He most often published in these fields:
- Genetics (39.83%)
- Epigenetics (25.54%)
- Cell biology (23.81%)
What were the highlights of his more recent work (between 2018-2021)?
- Epigenetics (25.54%)
- Computational biology (12.12%)
- Gene (15.58%)
In recent papers he was focusing on the following fields of study:
Peng Jin focuses on Epigenetics, Computational biology, Gene, Genetics and DNA.
His Epigenetics study integrates concerns from other disciplines, such as Methylation, Enhancer, Gene expression, DNA methylation and Cytosine.
He has researched Gene in several fields, including Age at menopause and Menopause.
His work on Genetics is being expanded to include thematically relevant topics such as Pathogenesis.
His FMR1 research integrates issues from Phenotype, Ovulation and RNA, Untranslated region.
His research in Neurodegeneration intersects with topics in Ataxia and Cell biology.
Between 2018 and 2021, his most popular works were:
- Expansion of Human-Specific GGC Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders. (69 citations)
- Dissecting differential signals in high-throughput data from complex tissues. (19 citations)
- Disease prediction by cell-free DNA methylation. (18 citations)
In his most recent research, the most cited papers focused on:
Genetics, Methylation, DNA methylation, Epigenetics and Disease are his primary areas of study.
The concepts of his Genetics study are interwoven with issues in Cerebellum, Tau protein and Pathogenesis.
His Pathogenesis research includes elements of Fragile X-associated tremor/ataxia syndrome, FMR1, Sphingolipid, Ataxia and Genetic screen.
His Methylation research is multidisciplinary, incorporating perspectives in Translation, Messenger RNA, Untranslated region and Nervous system.
His study in DNA methylation is interdisciplinary in nature, drawing from both Cytosine, Frontal lobe, Computational biology and Mutation rate.
His Epigenetics research is multidisciplinary, relying on both Marker selection and DNA Hydroxymethylation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
